Tranexamic acid use during total hip arthroplasty

Stoicea, Nicoleta; Moran, Kenneth R.; Abdel-Rasoul, Mahmoud; Glassman, Andrew H.; Ellis, Thomas J.; Ryan, John; Granger, Jeffrey F.; Joseph, Nicholas; Salon, Nathan; Ackermann, Wiebke; Rogers, Barbara; Niermeyer, Weston; Bergese, Sergio D.

doi:10.1097/md.0000000000010720

Cited by 22 publications

(17 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Husted et al [18] reported preoperative 10 mg/kg, followed by 1 mg/kg/h of continuous intravenous infusion of TXA for 10 h, and no increase in postoperative thrombosis-related events was observed. Another study reported [19] that intravenous infusion of aminocycline in total knee arthroplasty can reduce blood loss, but does not increase deep vein thrombosis and pulmonary embolism. Hines et al [20] reported that intravenous aminocycline can reduce the transfusion rate in total hip revision and does not increase the rate of deep vein thrombosis.…”

Section: Safety Of Intravenous Use Of Txamentioning

confidence: 99%

Intravenous administration of tranexamic acid to reduce blood loss during perioperative period in acetabular fracture surgery

Wang¹,

Yang²,

Zhu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Backgroud: some studys have reported that topical use of TXA can reduce perioperative blood loss in acetabular fracture surgery. We aim to investigate the effect of intravenous administration of tranexamic acid (TXA) on perioperative blood loss during acetabular fracture surgery Methods From January 2016 to May 2020, 85 patients undergoing surgical treatment with intravenous TXA administration for acetabular fractures at our department were retrospectively analyzed. The patients were divided into three groups according to dosage of TXA: Single treatment group: patients receiving intravenous infusion of TXA (15 mg/kg) 20 min before surgery (n = 33), repeated treatment group: patients receiving intravenous infusion of TXA (15 mg/kg) 20 min before surgery and intravenous infusion of TXA (10 mg/kg) at 3 h (n = 26), and multiple treatment group: patients receiving intravenous infusion of TXA (15 mg/kg) 20 min before surgery and intravenous infusion of TXA (10 mg/kg) at 3 and 6 h (n = 26). Total blood loss, intraoperative blood loss, postoperative hemoglobin drop, surgery-related transfusion rate, postoperative thrombosis rate, and operation time were compared among these three groups Results Total blood loss, intraoperative blood loss, postoperative hemoglobin drop, and drainage volume in the single treatment group, repeated treatment group, and multiple treatment group were 932.7.0 ± 181.8 ml, 624.2 ± 138.7 ml, 32.2 ± 5.3 g/l, and 100.1 ± 30.1 ml; 843.4 ± 153.0 ml, 567.3 ± 144.1 ml, 27.6 ± 3.8 g/l, and 86.1 ± 42.2 ml; and 748.0 ± 145.2 ml, 521.1 ± 98.1 ml, 24.4 ± 4.4 g/l, and 64.8 ± 29.0 ml, respectively; the values were significantly different between groups (P < 0.05). The surgery-related blood transfusion rates in the single treatment, repeated treatment, and multiple treatment groups were 51.5% (17/33), 23.0% (6/26), 19.2% (5/26), respectively. There was no statistically significant difference in surgery-related blood transfusion rates between groups Conclusions Intravenous administration of TXA in acetabular fracture surgery can reduce total blood loss, intraoperative blood loss, and postoperative hemoglobin drop without increasing the risk of venous thrombosis. Multiple administrations before surgery, and at 3 h and 6 h during surgery are more effective than single and repeated administration

show abstract

Section: Safety Of Intravenous Use Of Txamentioning

confidence: 99%

Intravenous administration of tranexamic acid to reduce blood loss during perioperative period in acetabular fracture surgery

Wang¹,

Yang²,

Zhu³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The studies were conducted in different areas, 3 in USA [14,15,19], 1 in Canada [13], 1 in Argentina [3], 1 in UK [16], and 1 in Germany [18]). Of the seven studies, 5 were retrospective COSs [3,[13][14][15]19], and 2 were prospective COSs [16,18]. Allogenic blood transfusion rate was reported in all seven studies [3, 13-16, 18, 19] and risk of VTE events in seven studies [3, 13-15, 16, 18, 19].…”

Section: Study Characteristics and Quality Assessmentmentioning

confidence: 99%

“…Different dosages of TXA and surgical procedure were used in the studies (Table 1). VTE prophylaxis was clearly referred to in four studies [14,16,18,19]. Table 2 summarized the quality assessment of the selected studies, and the NOS score ranged from 7 to 9, which indicated acceptable quality for these studies.…”

Section: Study Characteristics and Quality Assessmentmentioning

confidence: 99%

“…Furthermore, little has been written about the risk factors and rate of venous thromboembolic (VTE) events [deep venous thromboses (DVTs) and pulmonary emboli (PEs)] following RHA in the literature, especially in the TXA settings [12]. Currently, the efficacy and safety of IV TXA in RHA have been explored in several studies [3,[13][14][15][16][17][18][19]. However, the results of these studies were inconsistent, and most of these studies were designed as cohort observational study (COS).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of Intravenous Tranexamic Acid and the Risk of Allogenic Blood Transfusion in Revision Hip Arthroplasty: a Meta-Analysis of 4517 Patients

Sun

Gao

Feng

2020

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Revision hip arthroplasty (RHA) is associated with high rates of bleeding. Tranexamic acid (TXA) has been widely used in primary hip arthroplasty (PHA) to minimize blood loss and transfusions. This study aimed to evaluate the efficacy and safety of intravenous (IV) TXA in RHA. PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched to identify studies published up to June 2019. Potential studies evaluating the efficacy and safety of IV TXA during RHA were included. Risk ratio (RR) of allogenic blood transfusion (ABT) and venous thromboembolic (VTE) events in TXA and no-TXA groups were calculated. We summarized 7 cohort observational studies (COSs) including 4517 participants. Intravenous TXA had an association with a reduced risk of ABT [pooled RR = 0.578; 95% confidence interval (CI): 0.448 to 0.745] compared with no-TXA cohort in the perioperative period. No significant difference was seen in VTE events (pooled RR = 1.335; 95% CI: 0.586-3.040, P = 0.492) between TXA and no-TXA cohorts. Further subgroup analysis strengthened blood-sparing efficacy of TXA. IV TXA is associated with a lower risk of ABT following RHA, without increasing the risk of VTE. However, due to limited number of COSs, well-designed randomized controlled trials are required to draw concrete conclusions.

show abstract

“…Husted et al [17] reported preoperative 10 mg/kg, followed by 1 mg/kg/h of continuous intravenous infusion of TXA for 10 h, and no increase in postoperative thrombosis-related events was observed. Another study reported [18] that intravenous infusion of aminocycline in total knee arthroplasty can reduce blood loss, but does not increase deep vein thrombosis and pulmonary embolism. Hines et al [19] reported that intravenous aminocycline can reduce the transfusion rate in total hip revision and does not increase the rate of deep vein thrombosis.…”

Section: Safety Of Intravenous Use Of Txamentioning

confidence: 99%

Intravenous administration of tranexamic acid to reduce blood loss during perioperative period in acetabular fracture surgery

Wang

Yang

et al. 2019

Preprint

View full text Add to dashboard Cite

Backgroud:Literature have reported that topical use of TXA can reduce perioperative blood loss in acetabular fracture surgery.We aim to investigate the effect of intravenous administration of tranexamic acid (TXA) on perioperative blood loss during acetabular fracture surgery Methods:From January 2016 to October 2019, 85 patients undergoing surgical treatment with intravenous TXA administration for acetabular fractures at our department were retrospectively analyzed. The patients were divided into three groups according to dosage of TXA: Single treatment group: patients receiving intravenous infusion of TXA (15 mg/kg) 20 min before surgery (n = 33), repeated treatment group: patients receiving intravenous infusion of TXA (15 mg/kg) 20 min before surgery and intravenous infusion of TXA (10 mg/kg) at 3 h (n = 26), and multiple treatment group: patients receiving intravenous infusion of TXA (15 mg/kg) 20 min before surgery and intravenous infusion of TXA (10 mg/kg) at 3 and 6 h (n = 26). Total blood loss, intraoperative blood loss, postoperative hemoglobin drop, surgery-related transfusion rate, postoperative thrombosis rate, and operation time were compared among these three groups Results:Total blood loss, intraoperative blood loss, postoperative hemoglobin drop, and drainage volume in the single treatment group, repeated treatment group, and multiple treatment group were 932.7.0 ± 181.8 ml, 624.2 ± 138.7 ml, 32.2 ± 5.3 g/l, and 100.1 ± 30.1ml; 843.4 ± 153.0 ml, 567.3 ± 144.1ml, 27.6±3.8 g/l, and 86.1± 42.2 ml; and 748.0 ± 145.2ml, 521.1 ± 98.1ml, 24.4 ± 4.4g/l, and 64.8 ± 29.0 ml, respectively; the values were significantly different between groups (P <0.05). The surgery-related blood transfusion rates in the single treatment, repeated treatment, and multiple treatment groups were 51.5% (17/33), 23.0% (6/26), 19.2% (5/26), respectively. There was no statistically significant difference in surgery-related blood transfusion rates between groups Conclusions:Intravenous administration of TXA in acetabular fracture surgery can reduce total blood loss, intraoperative blood loss, and postoperative hemoglobin drop without increasing the risk of venous thrombosis. Multiple administrations before surgery, and at 3 h and 6 h during surgery are more effective than single and repeated administration

show abstract

Tranexamic acid use during total hip arthroplasty

Abstract: Administration of low-dose intravenous (IV) and intra-articular (IA) TXA does not appear to increase rates of adverse events and may be effective in minimizing blood loss, as reflected by Hb and Hct values following THA.

Cited by 22 publications

References 87 publications

Intravenous administration of tranexamic acid to reduce blood loss during perioperative period in acetabular fracture surgery

Intravenous administration of tranexamic acid to reduce blood loss during perioperative period in acetabular fracture surgery

Association of Intravenous Tranexamic Acid and the Risk of Allogenic Blood Transfusion in Revision Hip Arthroplasty: a Meta-Analysis of 4517 Patients

Intravenous administration of tranexamic acid to reduce blood loss during perioperative period in acetabular fracture surgery

Contact Info

Product

Resources

About